Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
Hendrik Schulze‐Koops, Klaus Krueger, Inka Vallbracht Vallbracht, Rebecca Hasseli, Alla Skapenko
Topics & Concepts
MedicineRituximabRheumatoid arthritisTocilizumabHydroxychloroquineCoronavirus disease 2019 (COVID-19)Antirheumatic AgentsDiseaseImmunologyRheumatologyImmune systemInternal medicineIntensive care medicineInfectious disease (medical specialty)AntibodyCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchAutoimmune and Inflammatory Disorders Research